AxoGen Acquires Distribution Rights For Avance Nerve Graft

AxoGen is all set to start full distribution of Avance Nerve Graft, human tissue product. It is intended to use in the reconstruction of damaged peripheral nerves for all surgeons who perform these procedures.

Avance is a decellularized and cleansed scaffold from donated human peripheral nerve. Beginning in July 2009, AxoGen is likely to begin full distribution of Avance.

Karen Zaderej, COO of AxoGen, said: “Avance Nerve Graft has proven to be a safe option to bridge the gap in damaged peripheral nerves. With our established relationships with surgeons and surgical practices across the country, AxoGen is well positioned to coordinate all distribution and marketing responsibilities for Avance moving forward.”